HTH-01-091 TFA

HTH-01-091 三氟乙酸

HTH-01-091 TFA

H659342-5mg

5mg

≥98%

-20°C储存

超低温冰袋运输

HTH-01-091 TFA is a potent and selective maternal embryonic leucine zipper kinase (MELK) inhibitor, with an IC 50 of 10.5 nM. HTH-01-091 TFA also inhibits PIM1/2/3 , RIPK2 , DYRK3 , smMLCK and CLK2 . HTH-01-091 TFA can be uesd for breast cancer research. Appearance:Solid IC50& Target:IC50: 10.5 nM (MELK), 41.8 nM (DYRK3), 42.5 nM (RIPK2), 60.6 nM (PIM1), 108.6 nM (smMLCK), 632 nM (mTOR), 962 nM (PIK3CA), 1230 nM (CDK7), 1740 nM (GSK3A) In Vitro:HTH-01-091 (1 μM) TFA selectively inhibits 4% of the kinases over 90%. HTH-01-091 (0-10 μM, 1 h) TFA is cell permeable and causes MELK degradation. HTH-01-091 (0-10 μM, 3 day) TFA exhibits minor antiproliferative effects in breast cancer cells. Biological Activity:HTH-01-091 TFA is a potent and selective maternal embryonic leucine zipper kinase (MELK) inhibitor, with an IC 50 of 10.5 nM. HTH-01-091 TFA also inhibits PIM1/2/3 , RIPK2 , DYRK3 , smMLCK and CLK2 . HTH-01-091 TFA can be uesd for breast cancer research.

C28H29Cl2F3N4O4

613.46 g/mol

O=C1N([C@H]2CC[C@H](CN(C)C)CC2)C3=C(CN1)C=NC4=CC=C(C5=CC(Cl)=C(O)C(Cl)=C5)C=C34.OC(C(F)(F)F)=O